The retinoic acid receptor alpha (RARA) gene is disrupted by PML/RARA fusion in acute promyelocytic leukemia (APL). The P2 promoter of RARA, controlling the RARa2 isoform, contains an RA-responsive element and may be targeted in APL. To test whether aberrant methylation of P2 was involved, 47 APL at diagnosis, 16 APL at first relapse, 50 acute myeloid leukemia (AML) and 22 acute lymphoblastic leukemia (ALL) were tested by methylation-specific polymerase chain reaction. RARA P2 methylation was highly associated with APL (APL: 25/63 vs AML/ALL: 2/75, Po0.0001). P2 methylation occurred at similar frequencies in APL at diagnosis and relapse, suggesting it was an initiating leukemogenic event. In the APL line NB4, RARa2 was not expressed, with the untranslocated RARA shown to be P2 methylated. 5-Azacytadine treatment of NB4 led to progressive P2 demethylation and re-expression of RARa2, confirming that RARA methylation collaborated with PML/RARA in totally suppressing RARa. In APL, RARA P2 methylation was unrelated to gender, age, presenting leukocyte counts and additional cytogenetic aberrations. For APL patients receiving all-trans retinoic acid for induction, P2 methylation did not affect the complete remission rates and survivals. RARA is the first myeloid-specific transcription factor shown to be dysregulated by both translocation and aberrant methylation.
Introduction
Retinoic acid receptor alpha (RARa) is an important transcription factor for myeloid differentiation. It is preferentially expressed in myeloid cells, 1, 2 and is upregulated in neoplastic promyelocytes upon induction of differentiation with retinoic acid (RA). 3 Furthermore, all-trans retinoic acid (ATRA) induces granulocytic maturation in the leukemic cell line HL60 through RARa homodimerization, or heterodimerization with retinoic X receptor (RXR) to form RARa/RXR, which results in the transactivation of genes with an RA-responsive element (RARE). 4 Finally, CEBPa, a major myeloid-specific transcription factor that induces terminal myeloid differentiation, is an RA-inducible target gene. 5 Therefore, granulocytic differentiation induced by RA is likely to be mediated by RARa. The key role of RARa in granulocytic maturation is further illustrated in acute promyelocytic leukemia (APL), where disruption of RARA by t (15;17) leads to leukemogenesis. 4 The human RARA gene comprises 10 exons, which encode the expression of two major isoforms of RARa, RARa1 and RARa2. They diverge in their N-terminal AF-1 domain, due to alternative promoter/exon usage and alternative splicing. 6 The promoter P1 generating mRNA for RARa1 is located 5 0 to exon 1, while the promoter P2 generating mRNA for RARa2 is located between exons 2 and 3. Interestingly, P2 but not P1 contains an RARE. This implies that RARa2 is an RA-inducible protein, but RARa1 is not. 7, 8 This is shown by the increased expression of RARa2 but not RARa1 during retinoid-induced differentiation of the GM-CSF-dependent MPRO cells, suggesting that the RARa2 isoform is a direct RA-activated target in myeloid differentiation. 9 Similarly, in the factor-dependent cell-Paterson (FCDP) mixA4 murine progenitor cells, a marked increase in RARa2 also occurred after growth factor-mediated myeloid differentiation. 7 These observations suggest that the RARa2 isoform is directly involved in myeloid differentiation. 9 Thus, while the expression of the RARa1 isoform is ubiquitous, the RARa2 isoform appears to be specifically associated with myeloid differentiation, particularly in response to RA. 10 DNA methylation, catalyzed by DNA methyltransferase, involves the addition of a methyl group to the carbon 5 position of the cytosine ring in the CpG dinucleotide and results in the generation of methylcytosine. [11] [12] [13] [14] In the normal mammalian genome, CpG dinucleotides have been progressively depleted during evolution, and thus are under-represented. In contrast, CpG-rich regions, 'CpG islands', exist inside the promoter of genes. In about 40-50% of human genes, the CpG islands are protected from methylation, so that these genes are transcriptionally active. In cancers, however, CpG islands of various genes have been shown to be aberrantly hypermethylated. This aberrant gene promoter methylation results in gene silencing, thus serving as an alternative mechanism of gene inactivation. 15, 16 Aberrant promoter methylation involving the p15, p16, p18, RB, p300, estrogen receptor (ER), E-Cadherin (E-Cad), retinoblastoma protein-interacting zing-finger gene 1, caspase-8, von Hippel-Lindau and O 6 -methylguanine-DNA methyltransferase genes has been studied in acute leukemia, with preferential methylation of groups of genes in different leukemia subtypes. [17] [18] [19] [20] [21] [22] In view of the critical role of RARa2 in myeloid differentiation, we examined if aberrant methylation of the P2 promoter controlling RARa2 expression might be involved in leukemogenesis.
Materials and methods

Patients and diagnosis
The diagnoses of acute leukemia were made according to the standard criteria. 23, 24 Diagnostic bone marrow samples -were obtained from 47 patients with APL, 50 patients with other subtypes of acute myeloid leukemia (AML) (M1: 12; M2: 20; M4: 6; M5: 9 and M6: 3) and 25 patients with acute lymphoblastic leukemia (ALL) (T cell: 2; pre-B: 1; early B precursor: 3; common: 19). In addition, marrow samples of another 16 APL patients at first relapse were studied.
Methylation-specific polymerase chain reaction (MSP)
High molecular weight DNA was isolated from bone marrow aspirates at diagnosis by standard protocols. The MSP was performed as described previously. 17, 25, 26 Treatment of DNA with bisulfite for conversion of unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed with a commercially available kit (CpGenome DNA modification kit, Intergen, Burlington, NY, USA) according to the manufacturer's instructions. The primers for the methylated and unmethylated RARA promoter P2 are shown in Table 1 . The RARA promoter P2 sequence mapped to nucleotides (nt) 1-670 (GenBank accession number: AF283809), where a CpG island with CG content of 450% was identified, starting from nt 285 to 624 (Figure 1a ). Bisulfite-treated DNA (1 mg) was amplified in duplicate by MSP, and the PCR products were analyzed by polyacrylamide gel electrophoresis and ethidium bromide staining. DNA from eight normal donors was used as negative control, while methylated control DNA (CpGenome Universal Methylated DNA, Intergen) was used as positive control in all the experiments. The primer sequences for amplification of the methylated allele (M-MSP) and unmethylated allele (U-MSP), and the MSP conditions are shown in Table 1 . The methylation status of the retinoic acid receptor beta (RARB) gene was also studied by MSP as described previously. 20 
Specificity and sensitivity of MSP
The identity of the methylated and unmethylated PCR products was confirmed by automated DNA sequencing bidirectionally (ABI 377, PE Biosystems). To define the sensitivity of MSP, 1 mg of methylated control DNA (Intergen) was serially 10-fold diluted in normal DNA, modified by bisulfite and amplified with primers for the methylated RARA P2 sequences.
5-Azacytidine (5-AC) treatment of NB4
The APL cell line NB4 was cultured in RMPI supplemented with 10% fetal calf serum. Treatment with 3 mM of 5-AC (Sigma, St Louis, MI, USA) (these concentrations were determined in previous experiments to give maximal response, data not shown) was performed at an initial NB4 cellular concentration of 10 6 /ml. Cells were harvested on days 0, 1, 2 and 4, and were examined morphologically after Wright-Giemsa staining, and for evidence of maturation with nitroblue tetrazolium reduction Table 1 Sequence of primers and annealing temperatures for MSP for RARA P2 promoter, and for Q-PCR of RARA and GAPDH The Q-PCR reactions were set up in one single tube with a reaction volume of 50 ml using the one-step EZ-RT-PCR kit (PE Biosystems), containing 100 ng of total RNA, and forward/reverse primers and the TaqMan probe for RARA and GAPDH genes. Thermal cycling conditions were: 501C for 2 min, cDNA synthesis at 601C for 30 min, denaturation at 951C of 5 min, 40 cycles at 941C for 30 s and specific annealing temperature for 1 min. Q-PCR data were collected continuously and analyzed with the ABI sequence detector system (PE Biosystems). test by standard protocols. Untreated NB4 cells were used as negative control for these experiments.
Quantification of mRNA of the RARa2 isoform by quantitative polymerase chain reaction (Q-PCR)
Quantification of mRNA of the RARa2 isoform against an endogenous control gene GAPDH was performed by real-time Q-PCR (ABI Prism 7700, PE Biosystems) as described previously. 27 Q-PCR of GAPDH was performed both as a control for RNA integrity and normalization of RNA loading. Total RNA was extracted serially from NB4 cells cultured with 5-AC on days 0, 1, 2 and 4. Q-PCR primers and the TaqMan probes duallabeled at the 5 0 -end with 6-carboxyfluorescein (FAM) and the 3 0 -end with 6-carboxytetramethylrhodamine (TAMRA) were designed with the Primer Express software (Version 1.5, PE Biosystems). The sequence and relative location of primers and Q-PCR conditions are shown in Table 1 and Figure 1b . All samples were tested in triplicate. Cycle thresholds (C T ), at which a significant increase in fluorescence signal was first detected, were set at a minimum of 10 s.d. above the mean baseline fluorescence calculated from cycles 1 to 15. Standard curves for RARA and GAPDH were generated by plotting the C T 's against the logarithm of the starting amount of a serial dilution (0.4-100 ng) of normal RNA. RARA expression relative to GAPDH was quantified by the comparative C T method, 27 by subtracting the C T of the RARA from the GAPDH to obtain the DC T . The fold difference between RARA and GAPDH was given by 2 DCT .
Statistical analysis
Frequency of RARA methylation in APL, AML and ALL patients was compared by w 2 or Fisher's exact test. Disease-free survival (DFS) was measured from complete remission (CR) to relapse. Overall survival (OS) was determined from the date of diagnosis to death or last follow-up. In the 63 APL patients, the frequency of RARA P2 methylation in samples at diagnosis and relapse were compared by w 2 or Fisher's exact test. Of the 47 APL patients studied at diagnosis, 44 received ATRA induction therapy and three with combination chemotherapy. In these 47 diagnostic samples, RARA P2 methylation was correlated with sex and additional cytogenetic aberrations (for cases with full karyotypes available) by w 2 or Fisher's exact test, and age and leukocyte count by Student's t-test. For the 44 APL patients receiving ATRA induction therapy, the impact of RARA methylation on CR rate was studied by w 2 or Fisher's exact test, and DFS and OS were analyzed by the Kaplan-Meier product-limit method and compared by the log-rank test. The association between RARA and RARB methylation was analyzed by Fisher's exact test. All P-values were two-sided.
Results
MSP in controls and cell lines
DNA from eight normal donors was all negative for RARA P2 methylation (Figure 2a) . The specificity of the MSP was shown by DNA sequencing (Figure 2b ). The sensitivity of M-MSP was 10 À4 (Figure 2c ).
RARA P2 and RARB methylation in leukemia samples RARA P2 methylation was found in 25/63 (39.7%) of APL samples, but only in 1/50 non-M3 AML (Figure 2d and e) and 1/25 ALL samples (10/30 in APL vs 2/75 in AML/ALL, Po0.0001). In all, 29 APL patients had previously been analyzed for methylation of RARB. 20 Of these, six (21%) had methylation of RARB, and nine (31%) had P2 methylation of RARA. Methylation of RARA and RARB was unrelated (P ¼ 0.99). RARA P2 methylation was comparable in frequency at presentation and relapse (19/47, 40% vs 6/16, 38%, P ¼ 0.59).
RARA P2 methylation and gene expression in NB4
RARA P2 was completely methylated in NB4, as shown by positive amplification in M-MSP but not U-MSP (Figure 3a) . Consistent with complete gene methylation, no RARA transcript was detectable by Q-PCR. Treatment with 5-AC resulted in Clinicopathologic and prognostic significance of RARA P2 methylation
Of the 47 APL patients studied at diagnosis, RARA P2 methylation was not related to gender (male: 11/23 vs female: 6/24, P ¼ 0.38), mean age (methylated: 39.6 vs unmethylated: 40 years, P ¼ 0.93), the mean presenting leukocyte count (methylated: 28.8 vs unmethylated: 19.7 Â 10 9 /l, P ¼ 0.48) and additional cytogenetic aberrations (positive: 6/10 vs negative: 11/26, P ¼ 0.29). For 44 patients receiving induction therapy with ATRA, patients with and without RARA P2 methylation had comparable 5-year OS (75 vs 77%, P ¼ 0.85) and DFS (48 vs 51%, P ¼ 0.45).
Discussion
In this study, we showed that aberrant methylation of RARA P2 occurred almost exclusively in APL and not in other subtypes of AML or ALL, strongly suggesting RARA methylation to be specifically involved in the pathogenesis of APL. The specific impact of RARA alteration in APL is supported by the clinical observation that the disruption of RARA by t(15;17) results in APL but not other AML subtypes, 4, 28 and that mutation or translocation involving RARA have not been detected in other AML subtypes. 29, 30 RARA P2 methylation was found at comparable frequencies at diagnosis and relapse, suggesting that it occurred at disease initiation instead of disease progression. Furthermore, of the several genes found to be methylated in APL here and previously, including p15, p16, ER, E-Cad, RARB 20 and RARA, RARA appears to be the only gene specifically methylated in APL, as the others are methylated in a variety of other leukemias. Finally, it is intriguing to note that in APL, RARA is dysregulated by both translocation and aberrant methylation. Therefore, the genetic events leading to RARA methylation in APL should be further investigated.
To study the biologic significance of RARA P2 methylation, primary leukemia samples were unsuitable. This is because there is an inevitable contamination by residual normal marrow cells, which will interfere with the interpretation of the effect of P2 methylation on RARA expression. Therefore, we used the NB4 cell line as an in vitro model. In NB4, the RARA breakpoint maps to nt 16268 (GenBank accession number: AJ297538), 31 meaning that the RARA gene is fused to the PML gene from nt 16269 onwards. The RARA P2 promoter, which maps to nts 619-10300, resides in the reciprocal RARA/ PML gene and can no longer control the production of an intact RARa (Figure 1a) . Therefore, the production of normal RARa relies solely on the untranslocated allele. As RARA transcription was absent in NB4, the methylation of P2 must have occurred at the untranslocated allele. Thus, RARA methylation collaborated with PML/RARA fusion in completely abrogating RARa expression. This pattern of gene inactivation via disruption of one allele and methylation of the other is reminiscent of inactivation of a tumor suppressor gene according to Knudson's hypothesis. 32 Indeed, in another breast cancer cell line MCF-7 with repressed RARA, enforced expression of RARa2 resulted in growth inhibition. 33 Therefore, the oncogenic relevance of RARA silencing warrants further investigations and validation.
The leukemogenic action of PML/RARA is mediated through recruitment of the nuclear corepressor-histone deacetylase complex. 34 Moreover, PML/RARA might recruit DNA methyltransferase, leading to the methylation of RARB, a gene with an RARE and therefore potentially regulated by RA. 35 Importantly, RA treatment resulted in RARB gene re-expression, and terminal granulocytic differentiation. Furthermore, methylation of RARB was responsible for differentiation block in PML/RARA-transfected cells, thereby providing a direct mechanistic link between genetic and epigenetic changes in the pathogenesis of APL. 35 This implies that the leukemogenic potential of PML/RARA might in part be mediated through hypermethylation of RARB. Similar to RARB, RARA P2 also possesses an RARE, and has been shown to be a target of RARa transactivation. 4 Furthermore, RARA (the RARa2 isoform) is also upregulated during RA treatment of APL leukemic cells. 3 This implies that RARA might also be a potential candidate for PML/RARA-mediated gene methylation. Had this been the case, RARA and RARB methylation might be expected to be correlated. Instead, we showed that methylation of the two genes occurred separately in our APL patients, suggesting that RARA methylation might be an independent event that collaborates with PML/RARA in APL leukemogenesis. The role of RARB methylation in APL remains uncertain. RARB is not expressed normally during granulopoiesis. 36 Besides, RARB methylation has been detected in a wide range of cancers other than APL, including AML subtypes other than APL. 37 In contrast, RARa2 is normally expressed in granulopoiesis, plays an important role in myeloid differentiation 8 and is shown in this study to be preferentially targeted in APL. Thus, RARA P2 methylation leading to transcriptional suppression of RARa2 might be more important than RARB methylation in the pathogenesis of APL. 33 On treatment of NB4 with 5-AC, the RARA P2 was partially demethylated, which was associated with re-expression of RARa2. However, despite RARA demethylation and re-expression of RARa2, no evidence of differentiation was observed. This might be due to the lack of RA essential for the dimerization of RARa/RXR, which leads to downstream transactivation events and terminal granulocytic maturation.
The importance of secondary genetic events such as aberrant gene methylation in APL is also supported by observations in PML/RARA transgenic mice. 38, 39 In these transgenic mice, an APL-like illness develops only after a prolonged latency, implying that PML/RARA alone might be necessary but not sufficient to cause APL. 28 Aberrant promoter methylation may be one of the collaborating events, as frequent and selective gene methylation occurs in APL. 20 Finally, in contrast to the negative prognostic impact of p15 methylation on DFS in APL, 17 RARA methylation did not affect survivals. As RARA is important for myeloid differentiation, and pharmacologic dose of ATRA is able to overcome the differentiation block due to dysregulation of RARA, the lack of prognostic significance of RARA methylation in patients treated with ATRA might be expected. If this were the case, it would be interesting to define the prognostic impact of RARA methylation in historical controls who were treated by combination chemotherapy instead of ATRA.
In summary, RARA P2 methylation is specific to APL and may be important in APL leukemogenesis. Moreover, RARA methylation represents a prototype where a myeloid-specific transcription factor is dysregulated by both translocation and aberrant methylation.
